Arizona State Retirement System Acquires Shares of 5,805 Keros Therapeutics, Inc. (NASDAQ:KROS)

Arizona State Retirement System acquired a new stake in Keros Therapeutics, Inc. (NASDAQ:KROS) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 5,805 shares of the company’s stock, valued at approximately $231,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in KROS. JPMorgan Chase & Co. boosted its position in Keros Therapeutics by 13.0% during the first quarter. JPMorgan Chase & Co. now owns 37,528 shares of the company’s stock valued at $2,041,000 after purchasing an additional 4,329 shares in the last quarter. MetLife Investment Management LLC boosted its position in Keros Therapeutics by 55.0% during the first quarter. MetLife Investment Management LLC now owns 8,455 shares of the company’s stock valued at $460,000 after purchasing an additional 2,999 shares in the last quarter. Rhumbline Advisers raised its stake in Keros Therapeutics by 14.3% in the first quarter. Rhumbline Advisers now owns 15,886 shares of the company’s stock valued at $864,000 after buying an additional 1,984 shares during the last quarter. BlackRock Inc. raised its stake in Keros Therapeutics by 0.9% in the first quarter. BlackRock Inc. now owns 1,298,046 shares of the company’s stock valued at $70,588,000 after buying an additional 11,520 shares during the last quarter. Finally, Allianz Asset Management GmbH raised its stake in Keros Therapeutics by 57.6% in the first quarter. Allianz Asset Management GmbH now owns 75,391 shares of the company’s stock valued at $4,100,000 after buying an additional 27,544 shares during the last quarter. Institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Stock Down 1.1 %

Shares of NASDAQ:KROS opened at $58.28 on Monday. Keros Therapeutics, Inc. has a 52-week low of $27.02 and a 52-week high of $73.00. The stock has a market cap of $2.10 billion, a price-to-earnings ratio of -11.21 and a beta of 1.26. The business has a 50-day moving average price of $63.82 and a 200-day moving average price of $47.23.

Keros Therapeutics (NASDAQ:KROS) last announced its quarterly earnings data on Friday, March 1st. The company reported ($1.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.37) by $0.03. The firm had revenue of $0.14 million during the quarter. During the same period last year, the firm posted ($1.09) EPS. As a group, equities analysts anticipate that Keros Therapeutics, Inc. will post -5.11 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. HC Wainwright reiterated a “buy” rating and issued a $100.00 price target on shares of Keros Therapeutics in a research note on Friday, March 1st. Truist Financial reiterated a “buy” rating and issued a $100.00 price target on shares of Keros Therapeutics in a research note on Wednesday, March 13th. Wedbush reiterated an “outperform” rating and issued a $86.00 price target on shares of Keros Therapeutics in a research note on Thursday, February 29th. William Blair reiterated an “outperform” rating on shares of Keros Therapeutics in a research note on Wednesday, February 21st. Finally, Piper Sandler reiterated an “overweight” rating and issued a $105.00 price target on shares of Keros Therapeutics in a research note on Wednesday, March 27th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $86.00.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.